Cantor Fitzgerald analyst Brandon reiterated an Overweight rating on AcelRx and raised his price target to $9 from $8 after the approval of Dsuvia and the company’s Q3 earnings results. Folkes believes the approval of Dsuvia remained discounted in the stock’s price, given the opioid crisis, and now that an overhang has been removed, investors can look forward to the commercial potential of Dsuvia. Additionally, the analyst believes AcelRx’s second product, Zalviso, has the potential to gain approval in the U.S. over the next 12 months.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.